The present work describes a validated reverse phase high performance liquid chromatographic method for simultaneous estimation of Irbesartan chlorthalidone and cilnidipine in tablet dosage form. The quantification was carried out using C18 column (250 x 4.6mm, 5μm) and mobile phase comprised of Buffer, Acetonitrile and TEA in a proportion of 80:20:0.1 %v/v/v. The flow rate was 1.0 ml/min and the eluent was monitored at 222 nm. The selected chromatographic conditions were found to effectively separate Irbesartan Chlorthalidone and cilnidipine were 3.807 min, 4.667 min, and 6.887 min respectively. Linearity was found to be in the range of 30-90 μg/ml, 1.25-3.75 μg/ml and 1-3 μg/ml for Irbesartan Chlorthalidone and cilnidipine respectively. The percentage recoveries of all the drugs were found to be 99.27-99.81%, 99.57-99.99% and 99.22-99.44% for Irbesartan, chlorthalidone, and cilnidipine. The proposed method was found to be fast, accurate, precise, and reproducible and can be used for simultaneous estimation of these drugs in a tablet.
INTRODUCTION
Irbesartan is an angiotensin converting enzyme blocker As with all angiotensin II receptor antagonists, irbesartan is indicated for the treatment of hypertension. It may also delay progression of diabetic nephropathy and is also indicated for the reduction of renal disease progression in patients with type 2 diabetes, hypertension and microalbuminuria (>30 mg/24 hours) or proteinuria (>900 mg/24 hours)
Chlorthalidone is a diuretic drug used to treat hypertension, Compared with other medications of the thiazide class, chlortalidone has the longest duration of action but a similar diuretic effect at maximal therapeutic doses.Chlorthalidone of (RS)-2-Chloro-5-(1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl)benzene-1-sulfonamide, represents the class of Chlortalidone is a diuretic drug used to treat hypertension Chlortalidone has the longest duration of action but a similar diuretic effect at maximal therapeutic doses., used as an Antihypertensive agent. [1] [2] Chlorthalidone inhibits sodium ion transport across the renal tubular epithelium in the cortical diluting segment of the ascending limb of the loop of Henle. By increasing the delivery of sodium to the distal renal tubule, Chlorthalidone indirectly increases potassium excretion via the sodium-potassium exchange mechanism. The individual and combination with other drugs determination of Chlorthalidone has been carried out by UV spectrophotometer 3 , RP-HPLC 4-6 in bulk and solid dosage forms. Cilnidipine of O3-(2-
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,5-dicarboxylate belongs to Anti hypertensive. [7] [8] [9] Literature survey revealed that few analytical methods have been reported for the estimation of Cilnidipine included RP-HPLC 10-11 UV spectrophotometer. [12] [13] .Cilnidipine is a dual L-/N-type calcium channel protein inhibitor and blocker. Cilnidipine has displayed renal and vascular protective effects and improved baroreflex sensitivity in patients with hypertension. The present work describes a validated reverse phase HPLC method for simultaneous determination of these drugs in tablets.
MATERIALS AND METHODS
Reagents and Chemicals: Irbesartan, chlorthalidone and cilnidipine were received as a gift sample from Molecule laboratory, Acetonitrile of HPLC grade, Triethyl amine of HPLC grade, Water of HPLC grade.
Instruments and Chromatographic Conditions: LC-10AT HPLC system was used for method development, degradation studies and validation. Data acquisition was performed on Spinchrom HPLC software. The separation were achieved on C18 (250 × 4.6 mm, 5μm) column. The column was maintained at room temperature and the eluent was monitored at 222 nm using UV detector. The mixture of Potassium dihydrogen phosphate buffer 0.05M (pH 3.5): Acetonitrile: TEA (80:20:0.1 v/v) at a flow rate of 1.0 ml/min was used as a mobile phase. The injection volume was 20μl.
Preparation of standard solutions:
Irbesartan standard stock solution: (600 μg/mL) A 60 mg of Irbesartan was weighed and transferred to a 100 mL volumetric flask. Volume was made up to the mark with methanol.
Cilnidipine standard stock solution: (20 μg/mL)
A 20 mg of Cilnidipine was weighed and transferred to a 100 mL volumetric flask. Volume was made up to the mark with methanol. Take 10ml from this solution and transferred to 100 mL volumetric flask and volume made up to the mark by mobile phase.
Chlorthalidone standard stock solution: (25 μg/mL)
A 25 mg of Chlorthalidone was weighed and transferred to a 100 mL volumetric flask. Volume was made up to the mark with methanol. Take 10ml from this solution and transferred to 100 mL volumetric flask and volume made up to the mark by mobile phase.
Preparation of standard solution of mixtures of Irbesartan (60 μg/mL),Cilnidipine (2 μg/mL) and Chlorthalidone (2.5 μg/mL) Take 1 mL from the Irbesartan stock solution, 1mL from Cilnidipine stock solution and 1mL from Chlorthalidone stock solution and transferred to 10 mL volumetric flask and volume made up to the mark by mobile phase which was used in particular trials.
Preparation of Mobile phase:
Potassium dihydrogen phosphate buffer 0.05M (pH 3.5): Acetonitrile: TEA (80:20:0.1 v/v)
Preparation of sample solution:
Take Crushed Tablet powder equivalent to 60 mg of Irbesartan, 2.5 mg Chlorthalidone and 2 mg of Cilnidipine was transferred to a 100 ml volumetric flask, and made up volume up to the mark with mobile phase. The solution was filtered through whatman filter paper no. 42 and first few drops of filtrate were discarded. 10 ml of this solution was diluted to 100 ml with mobile phase. The solution was injected 20 µl. The areas of resulting peak were measured at 222 nm.
Validation of RP-HPLC method 1 Linearity
The linearity for Irbesartan, Cilnidipine and Chlorthalidone were assessed by analysis of combined standard solution in range of 30-90 μg/ml, 1-3 μg/ml and 1.25-3.75 μg/ml respectively, 5,7.5,10,12.5,15 ml solutions were pipette out from the Stock solution of Irbesartan(60 μg/ml), Cilnidipine (2 μg/ml) and Chlorthalidone (2.5 μg/ml) and transfer to 100 ml volumetric flask and make up with mobile phase to obtain 30,45,60,75 and 90 μg/ml, 1,1.5,2,2.5 and 3 μg/ml and 1.25,1.875,2.5,3.125 and 3.75 μg/ml for Irbesartan, Cilnidipine and Chlorthalidone respectively
In term of slope, intercept and correlation co-efficient value. The graph of peak area obtained verses respective concentration was plotted.
Precision
Results should be expressed as Relative standard deviation (RSD) or coefficient of variance.
A. Repeatability
Standard solution containing Irbesartan (60 μg/ml), Cilnidipine (2 μg/ml) and Chlorthalidone (2.5 μg/ml) was injected six times and areas of peaks were measured and % R.S.D. was calculated.
B. Intra-day precision
Standard solution containing (30,60,90 µg/ml) of Irbesartan and (1,2,3 µg/ml) of Cilnidipine and (1.25,2.5,3.75 μg/ml) of Chlorthalidone were analyzed three times on the same day and % R.S.D was calculated.
C. Inter-day precision
Standard solution containing (30,60,90 µg/ml) of Irbesartan and (1,2,3 µg/ml) of Cilnidipine and (1.25,2.5,3.75 μg/ml) of Chlorthalidone were analyzed three times on the different day and % R.S.D was calculated.
Accuracy
For Irbesartan 30 µg/ml drug solution was taken in three different flask label A, B and C. Spiked 80%, 100%, 120% of standard solution in it and diluted up to 10ml. The area of each solution peak was measured at 222 nm. 
LOD and LOQ
The LOD was estimated from the set of 3 calibration curves used to determination method linearity. The LOD may be calculated as,
Where, SD= Standard deviation of Y-intercepts of 3 calibration curves.
Slope = Mean slope of the 3 calibration curves.
The LOQ was estimated from the set of 3 calibration curves used to determine method linearity. The LOQ may be calculated as, LOQ = 10 × (SD/Slope)
Where, SD = Standard deviation of Y-intercepts of 3 calibration curves.
Robustness
Following parameters were changed one by one and their effect was observed on system suitability for standard preparation.
1. Flow rate of mobile phase was changed (± 0.2 ml/min) 0.8 ml/min and 1.2 ml/min.
2. pH of Mobile phase was changed ( ± 0.2 ) 3.3 and 3.5. 
Linearity and Range
The linearity for Irbesartan, Cilnidipine and Chlorthalidone were assessed by analysis of combined standard solution in range of 30-90 μg/ml,1-3 μg/ml and 1.25-3.75 μg/ml respectively. Correlation co-efficient for calibration curve Irbesartan, Cilnidipine and Chlorthalidone was found to be 0.999 for all of three. 
Precision

I. Repeatability
The data for repeatability of peak area measurement for Irbesartan(60 μg/ml), Cilnidipine (2 μg/ml) and Chlorthalidone (2.5 μg/ml), based on six measurements of same solution of Irbesartan (60 μg/ml), Cilnidipine (2 μg/ml) and Chlorthalidone (2.5 μg/ml) are depicted in table. The % RSD for Irbesartan, Chlorthalidone and Cilnidipine were found to be 0.271, 0.249 and 0.154 respectively. 
Robustness:
The effect of changes was found to be within the acceptance criteria as shown in The assay results were comparable to labeled value of each drug in Tablet dosage form. These results indicate that the developed method is accurate, precise, simple and rapid. It can be used in the routine quality control of dosage form in industries.
CONCLUSION
From the above discussion it can be concluded that the proposed method is precise, accurate and stability indicating. Results are in good agreement with label claim which indicates there is no interference of excipients. Therefore the proposed method can be used for routine analysis of Irbesartan Chlorthalidone and Cilnidipine in combined tablet formulation.
